Searchable abstracts of presentations at key conferences in endocrinology

ea0056p1135 | Thyroid cancer | ECE2018

Improved prognostic value of the eighth edition of the AJCC/TNM staging system for differentiated thyroid cancer

van Velsen Evert , Stegenga Merel , van Kemenade Folkert , Kam Boen , van Ginhoven Tessa , Visser W Edward , Peeters Robin

Background: In January 2018, the 8th edition of the AJCC/TNM staging system for differentiated thyroid cancer (DTC) was introduced in clinical practice. Studies evaluating this 8th edition so far only comprised patients with papillary thyroid cancer (PTC) or made no distinction between PTC and follicular thyroid cancer (FTC). Therefore, we evaluated the prognostic value of the AJCC/TNM 8th edition in a European population with DTC, and subsequently distinguished PTC and FTC pa...

ea0056gp230 | Thyroid Cancer - Diagnostics & Treatments | ECE2018

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

Beukhof Carolien , Brabander Tessa , van Nederveen Francien , van Velthuysen Loes , van Kemenade Folkert , de Rijke Yolanda , Froberg Lideke , Kam Boen , de Herder Wouter , Peeters Robin

Aim: To evaluate the effectiveness of Peptide Receptor Radionuclide Therapy with 177Lu-octreotate (PRRT) for medullary thyroid carcinoma (MTC).Background: There are few therapeutic options for progressive metastatic MTC. The Erasmus MC Center for Neuroendocrine Tumors has been at the forefront of developing PRRT for neuroendocrine tumors. PRRT has also been suggested to be a useful treatment for MTC, but evidence is very limited.<p class="...